Baird Upgrades Biogen to Outperform, Raises Price Target to $340

This agreement marks the fourth U.S. retiree buyout since the beginning of 2021 and reflects a continuation of efforts to reduce pension liabilities, volatility and cost while securing retiree pension benefits with